The investigation conducted to determine whether Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. and Roche Müstahzarları San. A.Ş. violated Article 4 of the Act no 4054 in order to increase the use of Lucentis, which is more expensive than Altuzan, was concluded. Lucentis and Altuzan are used for eye diseases.

As a result of the discussion of the file by the Competition Board on 21.01.2021, it was decided that Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. and Roche Müstahzarları San. A.Ş. violated Article 4 of the Act no 4054; therefore, administrative fines shall be imposed on the said undertakings pursuant to Article 16 of the same Act.

Click here for the pronouncement of the decision dated 21.01.2021 and no 21-04/52-21, the reason of which will be notified later and which can be appealed before Ankara Administrative Courts.